Skip to content

Effect of Intravascular Laser Irradiation of Blood (ILIB) Laser on muscle damage, funcitional capacity and biomarkers in atheletes

Effect of ILIB laser on muscle damage, functional capacity and biomarkers in athletes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9zjghmk
Enrollment
Unknown
Registered
2024-08-28
Start date
2023-06-16
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biomechanical Phenomena

Interventions

This is a non-randomized, non-controlled clinical study with a convenience sample. The laser intervention will be applied to high-performance athletes for 30 minutes three times a week before regular
E02.594.540

Sponsors

Universidade Federal de Ciências da Saúde de Porto Alegre
Lead Sponsor
Universidade Federal de Ciências da Saúde de Porto Alegre
Collaborator

Eligibility

Age
16 Years to 30 Years

Inclusion criteria

Inclusion criteria: Both sexes; age between 16 and 30; sign the Free and Informed Consent Form (FICF) for athletes over 18 years of age; sign and Informed Consent Form (ICF) for athletes under 18 years of age

Exclusion criteria

Exclusion criteria: Functional (musculoskeletal) incapacity; be undergoing of treatment

Design outcomes

Primary

MeasureTime frame
ILIB will promote a reduction in muscle damage resulting from competitive sport, which will be assessed using muscle damage markers and functional tests. A reduction in the levels of pro-inflammatory markers such as TNF alpha, MCP-1, IL-6, CXCL-8, IL-1, IL-15, IL-17A, IL-5, IL-13, INF gamma, c-reactive protein and an increase in anti-inflammatory cytokines such as IL-1ra, IL-4, IL-10, IL-33, TGF beta, transcription factor NFkbeta, soluble HLAG which will be analyzed by ELISA (Enzyme-Linked Immunosorbent Assay) using serum samples (ELISA Development Kit, 900-M21, Peprotech Inc, USA). Improvement in the functionality of the cellular profile of CD4+ (T helper), CD8+ (T cytotoxic), CD16+CD56+ (NK), CD4+CD25+FOXP3 (T regulatory) cells and reduction in activation markers PD-1, CTLA4, CD95+, CD28+CD57+ and HALDR through flow cytometry. Improvement in the redox balance through the reduction of nitric oxide (TBARS), improvement in the antioxidant activity of the enzymes superoxide dismutase (SOD) and catalase (CAT) and the content of glutathione (GSH) through biochemical assays. Improvement in functional capacity through analysis of the tests: Star Excursion Balance Test (SEBT), II.Tripple Hop for Distance Test (THDT) and Effort Perception Scale (EPE).

Secondary

MeasureTime frame
No secondary outcomes are expected.

Countries

Brazil

Contacts

Public ContactAlessandra Peres

Universidade Federal de Ciências da Saúde de Porto Alegre

peres@ufcspa.edu.br+55-51-999619331

Outcome results

None listed

Source: REBEC (via WHO ICTRP)